Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KRK-TTA
- Development stage
- Unknown
- Lead developer
- Lamark
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
**KRK-TTA** is an investigational therapeutic candidate being developed by **Lamark** (Lamark Biotech) for the treatment of **lung cancer**. According to company pipeline documentation, the asset is currently in **Phase 1/2** clinical development. Lamark Biotech specializes in the development of **tRNA-based medicines** designed to address diseases caused by nonsense mutations. Their platform utilizes engineered tRNAs to suppress premature stop codons, which allows the cellular machinery to read through the mutation and produce a full-length, functional protein. While the specific molecular target for KRK-TTA has not been publicly disclosed, the program represents an application of tRNA technology to oncology.
Beyond the preview
Go deeper on KRK-TTA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KRK-TTA.